Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

Yalcin, SuayibDane, FaysalOksuzoglu, BernaYildirim, NuriyeIsikdogan, AbdurrahmanOzkan, MetinDemirag, GuzinCoskun, Hasan SenolKarabulut, BulentEvrensel, TurkkanUstaoglu, Mehmet AliOzdemir, FeyyazTurna, HandeYavuzsen, TugbaAykan, FarukSevinc, AlperAkbulut, HakanYuce, DenizHayran, MutluKilickap, Saadettin2019-10-272019-10-2720180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.4_suppl.346https://hdl.handle.net/11454/30692Gastrointestinal Cancers Symposium -- JAN 18-20, 2018 -- San Francisco, CAen10.1200/JCO.2018.36.4_suppl.346info:eu-repo/semantics/closedAccessQuality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.Conference Object364WOS:000436174100331Q1